Hexima Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HXL.AX research report →
Price Chart
About the company
Hexima Limited is a biotechnology firm focused on the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. Its primary drug candidate, pezadeftide, a plant defensin, is presently undergoing Phase IIb clinical evaluations in Australia and New Zealand to address fungal toenail infections. The company was established in 1997 and its main operations are situated in Preston, Australia.
- CEO
- Geoffrey Paul Kempler
- IPO
- 2020
- HQ
- Preston, VIC, AU
Get TickerSpark's AI analysis on HXL.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $542.88K
- P/E
- -5.42
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 1.43
- EV/EBITDA
- 3.98
- Div Yield
- 11.54%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -14.90%
- ROIC
- -17.66%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-287,577
- Net Income
- $-503,831+46.0%
- EPS
- $-0.01+46.4%
- OCF Growth
- -293.6%
- FCF Growth
- -293.6%
- 52W High
- $0.02
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.66
- RSI (14)
- 16
- Avg Volume
- 0
No earnings-call transcripts are available for HXL.AX yet.
- Free Float
- 43.7%
- Shares Outstanding
- 41.76M
- Float Shares
- 18.26M
Our HXL.AX coverage
Recent articles, reports, and earnings notes.
No research on HXL.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HXL.AX report →